On one hand, elevated MMP9 levels in CRC patients, due to the intrinsic nature of the tumor environment, may predispose these individuals to an increased risk of developing CIPN when subjected to chemotherapy. The gene discussed is MMP9; the disease is colorectal carcinoma.